You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
AstraZeneca
McKesson

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: RE44681

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE44681
Title:Compositions and methods for inhibiting growth of SMAD4-deficient cancers
Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin .alpha..sub..nu..beta..sub.6, and the responsiveness of patient populations to .alpha..sub..nu..beta..sub.6-active compounds and compositions (e.g., antibodies and other ligands that bind .alpha..sub..nu..beta..sub.6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such .alpha..sub..nu..beta..sub.6-active compounds and compositions by examining the expression of .sub..nu..beta..sub.6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment/prevention of tumor progression using ligands, including antibodies and molecule drugs, that bind to integrin .alpha..sub..nu..beta..sub.6 on the surfaces of tumor cells and/or that block one or more components of the TGF-.beta. pathway, particularly in smad4-deficient tumor cells.
Inventor(s): Violette; Shelia M. (Lexington, MA), Koopman; Louise A. (Chestnut Hill, MA)
Assignee: Biogen Idec MA Inc. (Cambridge, MA)
Application Number:13/863,646
Patent Claims:see list of patent claims

Details for Patent RE44681

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Biogen Idec MA Inc. (Cambridge, MA) 2026-07-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
AstraZeneca
Colorcon
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.